Shares of biotech company Ziopharm Oncology (NASDAQ:ZIOP) were up more than 17% today, after the company announced that its phase 3 clinical trial for its experimental cancer drug palifosfamide reached enough progression-free survival events to initiate data collection and the statistical analysis of the study. With top-line results -- a major binary event for Ziopharm investors -- to be revealed in late March, health-care analyst Max Macaluso discusses today's stock-price surge and what Ziopharm investors need to watch.
Motley Fool Returns
Stock Advisor S&P 500
5 Years 53% 38%
17+ years 341% 95%
Stock Advisor launched in February of 2002. Returns as of 11/18/2019.Join Stock Advisor